Purification of Pluripotent Stem Cell-Derived Cardiomyocytes for Safe Cardiac Regeneration
- 502 Downloads
Human pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), have the potential to differentiate into various cells types and may be used as cell sources for regenerative medicine in the context of various diseases, including severe heart failure. However, one of the biggest hurdles in the use of human PSCs for clinical applications is tumor formation due to contamination with residual tumor-forming cells, primarily undifferentiated PSCs. In addition, hundreds of millions of cardiomyocytes are required for heart repair. Two approaches have been developed for achievement of safer cardiac regenerative therapy using human PSCs: (1) selective elimination of residual tumor-forming cells before cell transplantation and (2) purification of PSC-derived cardiomyocytes. Many methodologies, including genetic and nongenetic modification, have been developed using these strategies. In this chapter, we focus on the current status of selective elimination of residual PSCs and purification of cardiomyocytes for safe stem cell therapy.
KeywordsInduced pluripotent stem cell Embryonic stem cell Purification Cardiomyocyte Tumor
The present work was supported by the Highway Program for Realization of Regenerative Medicine from Japan Science and Technology Agency (to K.F.) and SENSHIN Medical Research Foundation (to S.T.).
Compliance with Ethical Standards
Conflict of Interest
The Shugo Tohyama declare that they have no conflict of interest. Keiichi Fukuda is a cofounder of Heartseed Inc.
This article does not contain any studies with human participants performed by any of the authors.
- Aalto-Setala K, Fuerstenau-Sharp M, Zimmermann ME, Stark K, Jentsch N, Klingenstein M et al (2015) Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PLoS One 10(5):e0126596Google Scholar
- Ben-David U (2013) Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12:162–179Google Scholar
- Bieberich E, Silva J, Wang G, Krishnamurthy K, Condie BG (2004) Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants. J Cell Biol 167:723–734. doi: 10.1083/jcb.200405144 CrossRefPubMedPubMedCentralGoogle Scholar
- Fong CY, Peh GS, Gauthaman K, Bongso A (2009) Separation of SSEA-4 and TRA-1-60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Stem Cell Rev 5:72–80. doi: 10.1007/s12015-009-9054-4 CrossRefGoogle Scholar
- Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S et al (2015) The registry of the international society for heart and lung transplantation: thirty-second official adult heart transplantation report–2015; focus theme: early graft failure. J Heart Lung Transplant 34(10):1244–1254PubMedPubMedCentralGoogle Scholar
- Shiraki N, Shiraki Y, Tsuyama T, Obata F, Miura M, Nagae G et al (2014) Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab 19(5):p780–p794Google Scholar
- Tateno H, Onuma Y, Ito Y, Minoshima F, Saito S, Shimizu M et al (2015) Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Rep 4(5):811–820Google Scholar